Radek C Skoda
Nuclear and cytosolic fractions of SOX2 synergize as transcriptional and translational co-regulators of cell fate.
Schaefer T, Mittal N, Wang H, Ataman M, Candido S, Lötscher J, Velychko S, Tintignac L, Bock T, Börsch A, Baßler J, Rao T, Zmajkovic J, Roffeis S, Loeliger J, Jacob F, Dumlin A, Schürch C, Schmidt A, Skoda R, Wymann M, Hess C, Schöler H, Zaehres H, Hurt E, Zavolan M, Lengerke C. Nuclear and cytosolic fractions of SOX2 synergize as transcriptional and translational co-regulators of cell fate. Cell Rep 2024; 43:114807.
03.10.2024Nuclear and cytosolic fractions of SOX2 synergize as transcriptional and translational co-regulators of cell fate.
03.10.2024Cell Rep 2024; 43:114807
Schaefer Thorsten, Mittal Nitish, Wang Hui, Ataman Meric, Candido Silvia, Lötscher Jonas, Velychko Sergiy, Tintignac Lionel, Bock Thomas, Börsch Anastasiya, Baßler Jochen, Rao Tata Nageswara, Zmajkovic Jakub, Roffeis Sarah, Loeliger Jordan, Jacob Francis, Dumlin Alain, Schürch Christoph, Schmidt Alexander, Skoda Radek C, Wymann Matthias P, Hess Christoph, Schöler Hans R, Zaehres Holm, Hurt Ed, Zavolan Mihaela, Lengerke Claudia
Iron is a modifier of the phenotypes of JAK2-mutant myeloproliferative neoplasms.
Stetka J, Usart M, Kubovcakova L, Rai S, Rao T, Sutter J, Hao-Shen H, Dirnhofer S, Geier F, Bader M, Passweg J, Manolova V, Dürrenberger F, Ahmed N, Schroeder T, Ganz T, Nemeth E, Silvestri L, Nai A, Camaschella C, Skoda R. Iron is a modifier of the phenotypes of JAK2-mutant myeloproliferative neoplasms. Blood 2023; 141:2127-2140.
27.04.2023Iron is a modifier of the phenotypes of JAK2-mutant myeloproliferative neoplasms.
27.04.2023Blood 2023; 141:2127-2140
Stetka Jan, Usart Marc, Kubovcakova Lucia, Rai Shivam, Rao Tata Nageswara, Sutter Joshua, Hao-Shen Hui, Dirnhofer Stefan, Geier Florian, Bader Michael, Passweg Jakob R, Manolova Vania, Dürrenberger Franz, Ahmed Nouraiz, Schroeder Timm, Ganz Tomas, Nemeth Elizabeta, Silvestri Laura, Nai Antonella, Camaschella Clara, Skoda Radek C
Anti-Platelet Factor 4/Heparin Antibody Formation Occurs Endogenously and at Unexpected High Frequency in Polycythemia Vera.
Meyer S, Steinmann E, Lehmann T, Muesser P, Passweg J, Skoda R, Tsakiris D. Anti-Platelet Factor 4/Heparin Antibody Formation Occurs Endogenously and at Unexpected High Frequency in Polycythemia Vera. Biomed Res Int 2017; 2017:9876819.
18.06.2017Anti-Platelet Factor 4/Heparin Antibody Formation Occurs Endogenously and at Unexpected High Frequency in Polycythemia Vera.
18.06.2017Biomed Res Int 2017; 2017:9876819
Meyer Sara C, Steinmann Eva, Lehmann Thomas, Muesser Patricia, Passweg Jakob R, Skoda Radek C, Tsakiris Dimitrios A
Erythropoietin receptor mutation--a rush of blood to the head?
Holbro A, Skoda R, Lundberg P, Passweg J, Buser A, Lehmann T. Erythropoietin receptor mutation--a rush of blood to the head?. Ann Hematol 2015; 94:1229-31.
14.03.2015Erythropoietin receptor mutation--a rush of blood to the head?
14.03.2015Ann Hematol 2015; 94:1229-31
Holbro Andreas, Skoda Radek C, Lundberg Pontus, Passweg Jakob, Buser Andreas, Lehmann Thomas
Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms.
Lundberg P, Karow A, Nienhold R, Looser R, Hao-Shen H, Nissen I, Girsberger S, Lehmann T, Passweg J, Stern M, Beisel C, Kralovics R, Skoda R. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood 2014; 123:2220-8.
29.01.2014Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms.
29.01.2014Blood 2014; 123:2220-8
Lundberg Pontus, Karow Axel, Nienhold Ronny, Looser Renate, Hao-Shen Hui, Nissen Ina, Girsberger Sabine, Lehmann Thomas, Passweg Jakob, Stern Martin, Beisel Christian, Kralovics Robert, Skoda Radek C
JAK2 V617F-mutated myeloproliferative neoplasia developing five years after wild-type JAK2 acute myeloid leukemia: a case report.
Girsberger S, Karow A, Lundberg P, Dirnhofer S, Lehmann T, Passweg J, Tichelli A, Skoda R, Rovó A. JAK2 V617F-mutated myeloproliferative neoplasia developing five years after wild-type JAK2 acute myeloid leukemia: a case report. Acta Haematol 2012; 129:23-5.
19.09.2012JAK2 V617F-mutated myeloproliferative neoplasia developing five years after wild-type JAK2 acute myeloid leukemia: a case report.
19.09.2012Acta Haematol 2012; 129:23-5
Girsberger Sabine, Karow Axel, Lundberg Pontus, Dirnhofer Stephan, Lehmann Thomas, Passweg Jakob R, Tichelli André, Skoda Radek C, Rovó Alicia
Transition to homozygosity does not appear to provide a clonal advantage to hematopoietic progenitors carrying mutations in TET2.
Schaub F, Lehmann T, Looser R, Hao-Shen H, Tichelli A, Skoda R. Transition to homozygosity does not appear to provide a clonal advantage to hematopoietic progenitors carrying mutations in TET2. Blood 2011; 117:2075-6.
10.02.2011Transition to homozygosity does not appear to provide a clonal advantage to hematopoietic progenitors carrying mutations in TET2.
10.02.2011Blood 2011; 117:2075-6
Schaub Franz X, Lehmann Thomas, Looser Renate, Hao-Shen Hui, Tichelli André, Skoda Radek C
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations.
Passamonti F, Elena C, Schnittger S, Skoda R, Green A, Girodon F, Kiladjian J, McMullin M, Ruggeri M, Besses C, Vannucchi A, Lippert E, Gisslinger H, Rumi E, Lehmann T, Ortmann C, Pietra D, Pascutto C, Haferlach T, Cazzola M. Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood 2011; 117:2813-6.
11.01.2011Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations.
11.01.2011Blood 2011; 117:2813-6
Passamonti Francesco, Elena Chiara, Schnittger Susanne, Skoda Radek C, Green Anthony R, Girodon François, Kiladjian Jean-Jacques, McMullin Mary Frances, Ruggeri Marco, Besses Carles, Vannucchi Alessandro M, Lippert Eric, Gisslinger Heinz, Rumi Elisa, Lehmann Thomas, Ortmann Christina A, Pietra Daniela, Pascutto Cristiana, Haferlach Torsten, Cazzola Mario
Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms.
Schaub F, Looser R, Li S, Hao-Shen H, Lehmann T, Tichelli A, Skoda R. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood 2010; 115:2003-7.
08.01.2010Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms.
08.01.2010Blood 2010; 115:2003-7
Schaub Franz X, Looser Renate, Li Sai, Hao-Shen Hui, Lehmann Thomas, Tichelli André, Skoda Radek C
Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2
Kralovics R, Cazzola M, Pietra D, Passamonti F, Tichelli A, Tiedt R, Brutsche M, Buser A, Teo S, Skoda R. Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. Blood 2005; 106:3374-6.
15.11.2005Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2
15.11.2005Blood 2005; 106:3374-6
Kralovics Robert, Cazzola Mario, Pietra Daniela, Passamonti Francesco, Tichelli André, Tiedt Ralph, Brutsche Martin, Buser Andreas S, Teo Soon-Siong, Skoda Radek C